These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 17418218)

  • 41. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study.
    Gurfinkel E; Bozovich G; Beck E; Testa E; Livellara B; Mautner B
    Eur Heart J; 1999 Jan; 20(2):121-7. PubMed ID: 10099908
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Mulhall H; Huck O; Amar S
    Microorganisms; 2020 Jun; 8(6):. PubMed ID: 32526864
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Association of Periodontitis and Peripheral Arterial Occlusive Disease-A Systematic Review.
    Kaschwich M; Behrendt CA; Heydecke G; Bayer A; Debus ES; Seedorf U; Aarabi G
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208079
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse events in people taking macrolide antibiotics versus placebo for any indication.
    Hansen MP; Scott AM; McCullough A; Thorning S; Aronson JK; Beller EM; Glasziou PP; Hoffmann TC; Clark J; Del Mar CB
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD011825. PubMed ID: 30656650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Microfibrillar-associated protein 4 variation in symptomatic peripheral artery disease.
    Hemstra LE; Schlosser A; Lindholt JS; Sorensen GL
    J Transl Med; 2018 Jun; 16(1):159. PubMed ID: 29884190
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis.
    Wong AYS; Chan EW; Anand S; Worsley AJ; Wong ICK
    Drug Saf; 2017 Aug; 40(8):663-677. PubMed ID: 28397186
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Infection and Atherosclerosis Development.
    Campbell LA; Rosenfeld ME
    Arch Med Res; 2015 Jul; 46(5):339-50. PubMed ID: 26004263
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Endothelial dysfunction and cardiovascular disease.
    Widmer RJ; Lerman A
    Glob Cardiol Sci Pract; 2014; 2014(3):291-308. PubMed ID: 25780786
    [No Abstract]   [Full Text] [Related]  

  • 49. Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis.
    Madrigal-Matute J; Lindholt JS; Fernandez-Garcia CE; Benito-Martin A; Burillo E; Zalba G; Beloqui O; Llamas-Granda P; Ortiz A; Egido J; Blanco-Colio LM; Martin-Ventura JL
    J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25095870
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Persistent C. pneumoniae infection in atherosclerotic lesions: rethinking the clinical trials.
    Campbell LA; Rosenfeld ME
    Front Cell Infect Microbiol; 2014; 4():34. PubMed ID: 24711989
    [No Abstract]   [Full Text] [Related]  

  • 51. Bacterial invasion of vascular cell types: vascular infectology and atherogenesis.
    Kozarov E
    Future Cardiol; 2012 Jan; 8(1):123-38. PubMed ID: 22185451
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Higher cystatin C level predicts long-term mortality in patients with peripheral arterial disease.
    Urbonaviciene G; Shi GP; Urbonavicius S; Henneberg EW; Lindholt JS
    Atherosclerosis; 2011 Jun; 216(2):440-5. PubMed ID: 21388623
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccination for atherosclerosis.
    de Carvalho JF; Pereira RM; Shoenfeld Y
    Clin Rev Allergy Immunol; 2010 Apr; 38(2-3):135-40. PubMed ID: 19554480
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Secondary prevention of atherosclerosis through chlamydia pneumoniae eradication (SPACE Trial): a randomised clinical trial in patients with peripheral arterial disease.
    Vainas T; Stassen FR; Schurink GW; Tordoir JH; Welten RJ; van den Akker LH; Kurvers HA; Bruggeman CA; Kitslaar PJ
    Eur J Vasc Endovasc Surg; 2005 Apr; 29(4):403-11. PubMed ID: 15749042
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: a randomized, double-blind, placebo-controlled trial.
    Wiesli P; Czerwenka W; Meniconi A; Maly FE; Hoffmann U; Vetter W; Schulthess G
    Circulation; 2002 Jun; 105(22):2646-52. PubMed ID: 12045171
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial.
    Leowattana W; Bhuripanyo K; Singhaviranon L; Akaniroj S; Mahanonda N; Samranthin M; Pokum S
    J Med Assoc Thai; 2001 Dec; 84 Suppl 3():S669-75. PubMed ID: 12002908
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Progression of peripheral arterial occlusive disease is associated with Chlamydia pneumoniae seropositivity and can be inhibited by antibiotic treatment.
    Krayenbuehl PA; Wiesli P; Maly FE; Vetter W; Schulthess G
    Atherosclerosis; 2005 Mar; 179(1):103-10. PubMed ID: 15721015
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Can long-term antibiotic treatment prevent progression of peripheral arterial occlusive disease? A large, randomized, double-blinded, placebo-controlled trial.
    Joensen JB; Juul S; Henneberg E; Thomsen G; Ostergaard L; Lindholt JS
    Atherosclerosis; 2008 Feb; 196(2):937-42. PubMed ID: 17418218
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.